Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Jeffrey L. Bennett, MD, PhD - University of Colorado Denver
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NMO Treatment: Rituximab<br />
anti-CD20 mAb that depletes B cells from pre-B<br />
through memory lineages<br />
Dosage: 1000 mg IV on days 0 and 15<br />
Repeat every 6 months or if B cells > 5%<br />
Benefits: ARR reduced to 0.0-0.3; EDSS<br />
reduction<br />
Adverse events: infusion reactions, infections,<br />
PML.<br />
McKeon et al. (2008). Neurology, 71:93.<br />
Cree et al. (2005). Neurology, 64:1270.<br />
Jacob et al. (2008). Arch Neurol 65:1443.<br />
Kim et al. (2011). Arch Neurol 68:1412.
Change language